Soleno Therapeutics (SLNO) Asset Utilization Ratio (2015 - 2026)
Soleno Therapeutics (SLNO) reported Asset Utilization Ratio of 0.49 for Q1 2026, up 48.6% on a QoQ basis from 0.33 in Q4 2025.
Soleno Therapeutics (SLNO) has 5 years of Asset Utilization Ratio data on file, last reported at 0.49 in Q1 2026.
- Quarterly Asset Utilization Ratio changed N/A year-over-year to 0.49 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.49 (changed N/A YoY) and the FY2025 annual result came in at 0.43, changed N/A from the prior year.
- Asset Utilization Ratio grew to 0.49 in Q1 2026 per SLNO's latest filing, from 0.33 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.49 in Q1 2026 and bottomed at 0.11 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 0.85 |
| 10 | Soleno Therapeutics | 2.76 Bn | 2.51 Bn | 93.41 Mn | 0.49 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.49 |
| Dec 31, 2025 | 0.33 |
| Sep 30, 2025 | 0.21 |
| Jun 30, 2025 | 0.11 |
| Jun 30, 2017 | 0.06 |
| Mar 31, 2017 | 0.10 |
| Dec 31, 2016 | 0.32 |
| Sep 30, 2016 | 0.12 |
| Jun 30, 2016 | 0.07 |
| Mar 31, 2016 | 0.07 |
| Dec 31, 2015 | 0.03 |
| Sep 30, 2015 | 0.02 |